• Explore /
  • Poster
  • / Tumor-specific MHC class II upregulation associated with response to anti-PD-L1 therapy in patients with urothelial cancer.

Tumor-specific MHC class II upregulation associated with response to anti-PD-L1 therapy in patients with urothelial cancer.

Abstract Poster

Authors

null

İlayda Hasakioğulları

CellCarta (Belgium), Antwerpen (Wilrijk ), Belgium

İlayda Hasakioğulları , Mark Kockx , Bernadett Szabados , Matthew Young , Thomas Powles

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Advanced/Metastatic Disease

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4584)

DOI

10.1200/JCO.2024.42.16_suppl.4584

Abstract #

4584

Poster Bd #

279

Abstract Disclosures

Similar Posters

Poster

2020 Genitourinary Cancers Symposium

MHCI and FOXP3 predicting outcome to neoadjuvant atezolizumab in sequential urothelial cancer tissue.

MHCI and FOXP3 predicting outcome to neoadjuvant atezolizumab in sequential urothelial cancer tissue.

First Author: Bernadett Szabados

First Author: Sun Young Kim

First Author: Deepak Kilari

First Author: Philipp Harter